MDT
97.97
-0.41%↓
VEEV
301.82
-1.22%↓
A
141.04
+1.79%↑
HQY
92.06
+4.03%↑
PHR.US
23.23
-0.43%↓
MDT
97.97
-0.41%↓
VEEV
301.82
-1.22%↓
A
141.04
+1.79%↑
HQY
92.06
+4.03%↑
PHR.US
23.23
-0.43%↓
MDT
97.97
-0.41%↓
VEEV
301.82
-1.22%↓
A
141.04
+1.79%↑
HQY
92.06
+4.03%↑
PHR.US
23.23
-0.43%↓
MDT
97.97
-0.41%↓
VEEV
301.82
-1.22%↓
A
141.04
+1.79%↑
HQY
92.06
+4.03%↑
PHR.US
23.23
-0.43%↓
MDT
97.97
-0.41%↓
VEEV
301.82
-1.22%↓
A
141.04
+1.79%↑
HQY
92.06
+4.03%↑
PHR.US
23.23
-0.43%↓
24h
Current
Min
Max
Income | 78M 75M |
---|---|
Sales | 5.5M 26M |
Profit margin | 288.656 |
Employees | 59 |
EBITDA | -73M -71M |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +125.35% upside |
Next Earnings | 11 Nov 2025 |
---|
Market Cap | -42M 598M |
---|---|
Previous open | 0 |
Previous close | 0 |
Past performance is not a reliable indicator of future results.
27 Feb 2025, 15:29 UTC
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 24 USD 125.35%
High 29 USD
Low 18 USD
Based on 7 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
7 ratings
7
Buy
0
Hold
0
Sell
Based on 7 analysts giving stock ratings to KemPharm Inc - Dist in the past 3 months.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$